Nektar Therapeutics (NKTR)
54.70
+3.58
(+6.99%)
USD |
NASDAQ |
Dec 12, 16:00
55.20
+0.50
(+0.92%)
After-Hours: 19:12
Nektar Therapeutics Research and Development Expense (Quarterly): 27.25M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly & Co. | 3.466B |
| Amicus Therapeutics, Inc. | 23.42M |
| Regeneron Pharmaceuticals, Inc. | 1.338B |
| Rigel Pharmaceuticals, Inc. | 7.353M |
| Zevra Therapeutics, Inc. | 3.432M |